Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Aspen Aerogels Inc (ASPN) vs Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Price & Performance

Aspen Aerogels IncTrade
Bio-Rad Laboratories, Inc. Class A Common StockTrade

Price performance (Past 24H)

Key statistics

Aspen Aerogels Inc vs Bio-Rad Laboratories, Inc. Class A Common Stock — how do they compare? Aspen Aerogels Inc trades at $6.13 (market cap $522.00M), while Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 18× Aspen Aerogels Inc's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Aspen Aerogels Inc nearer its low. Which is the better fit depends on your goals.

ASPNBIO
Market Cap
$522.00M$9.39B
Sector
TechnologyHealth
52-Week High
$8.82$356.25
52-Week Low
$2.57$241.71
Enterprise Value
$495.40M$9.14B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Aspen Aerogels Inc

ASPN's stock trades at $6.25, down 9.29% in the past 24 hours, with a bullish technical signal from moving averages but neutral oscillators. The company reported a net loss of $389.55M in 2025, with negative profit margins, though Q2 2026 revenue beat estimates and Q3 guidance projects sequential improvement. Recent news highlights growing Thermal Barrier sales and a Supplier of the Year award from General Motors.

The outlook remains speculative; analyst consensus is strongly bullish (82.61% buy ratings), but persistent losses and high cash burn pose significant risks. Upside depends on execution of revenue growth and cost management, while downside risks include competitive pressures and failure to achieve profitability.

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Aspen Aerogels Inc

Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.

Read more on ASPN

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO